Open Access

Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer

  • Authors:
    • Yutao Liu
    • Fang Xu
    • Yubo Wang
    • Qingchen Wu
    • Buhai Wang
    • Yanwen Yao
    • Yu Zhang
    • Han Han‑Zhang
    • Junyi Ye
    • Lu Zhang
    • Xinru Mao
    • Zhe Zhang
    • Jing Liu
    • Liangjun Zhu
    • Renhua Guo
  • View Affiliations

  • Published online on: July 16, 2019     https://doi.org/10.3892/ol.2019.10625
  • Pages: 3159-3169
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Currently, in clinical settings, all TP53 mutations have been considered equally. However, numerous studies have demonstrated that the position and type of mutation have differential effects on prognosis. Such discrepancy can be partially due to the lack of unifying classification system for TP53 mutations. In the present study, two of the most frequently used systems were compared, according to the location of the mutation or its functional effects on p53 protein and the impact of TP53 mutations on the overall survival (OS) time of 379 Chinese patients with advanced lung cancer was analyzed. Capture‑based ultra‑deep targeted sequencing on plasma samples of 379 patients with advanced lung cancer was performed. The present results suggested that mutations occurring in exon 8 may be associated with shorter OS in tyrosine kinase inhibitor‑naïve patients (P=0.013) and in patients previously treated with one line of treatment (P=0.032). The results of the present study provided solid evidence that not all TP53 mutations were associated with a similar prognosis. Mutations in exon 8 were found in a subgroup of patients with unfavorable prognosis across various treatment histories. To the best of our knowledge, the present study is the first to compare different TP53 mutation classification systems in a large cohort of patients with advanced lung cancer.

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, Y., Xu, F., Wang, Y., Wu, Q., Wang, B., Yao, Y. ... Guo, R. (2019). Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer. Oncology Letters, 18, 3159-3169. https://doi.org/10.3892/ol.2019.10625
MLA
Liu, Y., Xu, F., Wang, Y., Wu, Q., Wang, B., Yao, Y., Zhang, Y., Han‑Zhang, H., Ye, J., Zhang, L., Mao, X., Zhang, Z., Liu, J., Zhu, L., Guo, R."Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer". Oncology Letters 18.3 (2019): 3159-3169.
Chicago
Liu, Y., Xu, F., Wang, Y., Wu, Q., Wang, B., Yao, Y., Zhang, Y., Han‑Zhang, H., Ye, J., Zhang, L., Mao, X., Zhang, Z., Liu, J., Zhu, L., Guo, R."Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer". Oncology Letters 18, no. 3 (2019): 3159-3169. https://doi.org/10.3892/ol.2019.10625